ClearPoint Neuro stock gains on recent momentum despite limited data

Published on 09/17/2026 at 20:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ClearPoint Neuro stock stands around the mid-teens in USD as of September 17, 2026, according to recent market snapshots. The medical devices company shows growing investor interest, supported by its neurosurgery focus.

CLPT, US18507C1099, Illustration mit AI erstellt.

ClearPoint Neuro stock (ISIN US18507C1099) is trading in the mid-teens in USD as of September 17, 2026, based on recent market portal overviews that list the company in the medical devices industry alongside a market capitalization of roughly USD 400 million.

Neuro-navigation specialist with growing footprint

ClearPoint Neuro, Inc. is a US-based medical technology company focused on providing MRI-guided neuro-navigation systems and related devices for neurosurgical procedures and drug delivery into the brain and central nervous system.

The company targets applications such as deep brain stimulation, biopsy, laser ablation and gene or cell therapy delivery, positioning its platform as an enabling technology for both hospital-based procedures and biopharmaceutical partners.

Recent trading context and valuation markers

Recent financial portal data as of mid-September 2026 place ClearPoint Neuro stock at around USD 13.40 with a daily gain near 1.90 percent, implying incremental positive trading momentum and a market capitalization of about USD 408.8 million.

At this price level the company’s valuation corresponds to the medical devices peer group segment, and the mid-teens share price suggests investors are assigning tangible value to its specialized neuro-navigation technology despite the company’s relatively small size compared with large-cap device makers.

Stock perspective for investors

For investors, the key checkpoints now are the company’s ability to convert its neurosurgery platform into recurring procedure revenue, expand its installed base of MRI-guided systems and deepen collaborations with pharmaceutical and biotech partners that rely on precise brain and spinal delivery solutions.